Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice

Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice

Abstract Dipeptidyl peptidase IV (DPP-IV) inhibitors improve glycemic control by prolonging the action of glucagon-like peptide-1 (GLP-1). In contrast to GLP-1 analogues, DPP-IV inhibitors are weight-neutral. DPP-IV cleavage of PYY and NPY gives rise to PYY3-36 and NPY3-36 which exert potent anorect...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Henrik H. Hansen, Rikke V. Grønlund, Tamara Baader-Pagler, Peter Haebel, Harald Tammen, Leif Kongskov Larsen, Jacob Jelsing, Niels Vrang, Thomas Klein
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/97a3ac05b965484c814efcbeef1dbf0b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares